Clinical Perspective on p 48
Endomyocardial biopsy can provide a confirmative diagnosis of cardiac sarcoidosis (CS) but is associated with low sensitivity. Imaging modalities such as positron emission tomography (PET) with fluorodeoxyglucose uptake and cardiac MRI (CMR), which may reveal early granulomatous disease, are being increasingly used for diagnosis of preclinical cardiac involvement. The specificity of PET and CMR imaging for diagnosis of CS is better than clinical criteria alone, although their role in long-term prognosis is still not clear. 5, 6 Implantable cardioverter defibril-lator (ICD) therapy has been shown to be effective in the prevention of sudden death in patients presenting with ventricular arrhythmias. 7, 8 However, the role of ICDs for primary prevention of sudden death in CS is not known.
We evaluated the risk of malignant ventricular arrhythmias and survival of patients with systemic sarcoidosis but without clinical manifestations of cardiac involvement. All patients demonstrated evidence of cardiac involvement on PET or CMR and underwent electrophysiological testing with programmed electric stimulation of the ventricle (PES) for risk stratification. We hypothesized that PES would predict the future risk of malignant ventricular arrhythmias and sudden death in patients who had evidence of CS based on imaging studies, but who did not have arrhythmic symptoms.
Methods

Patient Population
Seventy-six patients were included in this analysis. The institutional review board of the medical center approved the study. Consecutive patients with an established diagnosis of CS referred to the electrophysiology service for risk stratification between June 1998 and June 2008 who consented to have PES were included. Patients with history of prior ICD implantation or ventricular arrhythmia were excluded. All patients had extracardiac tissue biopsy-proven systemic sarcoidosis and evidence of CS as defined by typical imaging findings on either a CMR 9 or PET. CMR findings diagnostic of CS included localized intramyocardial increased signal intensity on T2-weighted sequence indicative of edema and delayed contrast enhancement suggestive of infiltration and scar-ring. PET was considered positive when perfusion images showed no evidence of ischemia and fluorodeoxyglucose (FDG) uptake images showed either increased or mismatched metabolic activity suggestive of infiltration, or matched decrease in metabolic activity indicative of scarring 5 (Figure 1 ).
Study Protocol
Electrophysiology studies were performed using a standard stimulation protocol. None of the patients were on antiarrhythmic medica- tions at the time of PES. Therapy with ␤ blockers and calcium channel blockers was not discontinued. Ventricular stimulation was performed using up to 3 premature beats at 2 drive-cycle lengths at both right ventricular apical and outflow tract pacing sites. Premature beats were delivered until refractoriness or to a minimum coupling interval of 200 ms. If no sustained ventricular arrhythmias were induced, burst ventricular pacing was performed from cycle lengths of 300 ms to 220 ms. If baseline stimulation failed to induce any arrhythmia, programmed stimulation was repeated during infusion with isoproterenol. The rate of infusion was titrated to increase sinus rate by 20%. Patients with inducible sustained ventricular arrhythmia during standard ventricular stimulation protocols were placed in the positive PES group. Sustained ventricular arrhythmias were defined by Ͼ30 seconds of sustained monomorphic ventricular tachycardia ( Figure 1 ), tachycardia requiring termination before 30 seconds because of hemodynamic instability, sustained polymorphic ventricular tachycardia. Ventricular fibrillation with triple premature beats of less than 220 ms was considered a nonspecific response and thus grouped in the noninducible category.
Demographic information and medication history were obtained by review of electronic medical records. An ECG recorded at the time of PES was interpreted. The 12-lead ECG was defined as abnormal if any of the following were present: QRS duration Ͼ120 ms; atrial fibrillation or flutter; Ͼ50% atrial or ventricular pacing; evidence of right ventricular hypertrophy in the absence of pulmonary arterial hypertension. The presence of prednisone, methylprednisolone, and/or hydrocortisone on the patient's medication list after the date of the PES was considered positive corticosteroid usage, regardless of dosage or duration. Mortality was ascertained by review of medical records and the Social Security Death Index. Event-free survival was calculated as the length of time from PES date to the date of first documented ventricular arrhythmia, death, or the end of the follow-up period, whichever came first. Follow-up period ended in July 2010. For each patient, all left ventricular ejection fraction (LVEF) measurements with a numeric value recorded on the institutional cardiovascular database were ascertained and dated from time of PES. In most cases, an LVEF was taken on the same date as the PES. The majority of additional LVEF measurements were available through echocardiography, PET, and CMR. When available, secondary LVEF measurements closest to 1 year after PES (up to 15 months), and closest to 2 years after PES (up to 27 months), were recorded. Nonnumeric measurements of LVEF were excluded.
It is noteworthy that, although the study by Aizer and Mehta et al 10 was completed at this institution, the patients in the present study are unique and reflect a more homogenous cohort, all of whom had evidence of CS based on imaging studies, but without symptoms of arrhythmias. None of the patients from that data set were included in the present study.
Statistical Analysis
Differences in distribution of baseline characteristics including age, sex, race, and corticosteroid use between patients in the positive PES group and negative PES group were evaluated using the 2 or Wilcoxon test, as appropriate. Sensitivities and specificities were calculated according to standard methods. 11 The Kaplan-Meier method was used to estimate event-free survival among patients in each group. The LVEF at 0, 1, and 2 years of the PES study across the 2 study groups were compared using the Wilcoxon test.
Results
Baseline clinical characteristics are listed in Table 1 . A majority of the patients in the study were female and black. Two thirds of the patients had received corticosteroids. There was no statistically significant difference in age, sex, race, corticosteroid use, or length of follow-up between the positive and negative PES groups (PϾ0.2 in all cases).
Eight of the 76 patients (10.5%) were inducible for sustained ventricular arrhythmia during PES and placed in the positive PES group. All 8 patients subsequently received ICD implantation. The remaining 68 patients were placed in the negative PES group and none received ICD implantation during the follow-up period. None of the patients in the EP negative group had evidence of significant AV conduction disease (HV Ͼ70 ms). Atrioventricular conduction times were not significantly different in the 2 groups (AH interval: 95Ϯ14.6 versus 85.5Ϯ28.3, HV: 58.2Ϯ11.1 versus 49.9Ϯ 13.4 in PES positive and negative groups, respectively). None of the patients in PES negative group had findings to warrant a pacemaker implantation. One patient in the EP positive group had evidence of prolonged HV of 85 ms, and was implanted with a dual-chamber defibrillator.
Compared with the negative PES group, mean LVEF was found to be significantly lower in the positive PES group at the time of the PES, a difference also seen 1 and 2 years after the procedure (PϽ0.05) ( Table 2) . Compared with measurements at time of PES, there was no significant reduction in LVEF in the PES negative group after 1 and 2 years. Using LVEF of 40% as a cutoff, 18 (26.5%) of 68 patients in the PES negative group had reduced ejection fraction as compared with 5 (62.5%) of the 8 in the PES positive group (Table 1) .
Event Rate
The event rate was 75% in PES positive group (2 patients died and 4 had appropriate ICD shocks for ventricular tachycardia) and 1.5% in the PES negative group (Ͻ0.0001). Six of the 8 patients in the positive PES group were alive at the end of the follow-up period with a median follow-up time of 5.6 years (range, 4.5 to 8.1 years). Four of the 6 had received appropriate ICD therapy for ventricular tachycardia; one patient who had appropriate shocks also has received inappropriate ICD shocks for atrial tachyarrhythmias. The 2 deaths occurred in patients with inducible sustained ventricular tachycardia. One occurred 2 months after ICD implantation; the cause of death could not be determined. The second died 18 months after ICD implantation from a ventricular arrhythmia storm that failed to respond antiarrhythmic therapy. Four of the 6 patients in the PES positive group who had arrhythmic events (ICD shocks or death) had LVEF of Ͻ40% at the time of PES. There was one death in the PES negative group from respiratory failure 5 1/2 years after PES. The other 67 patients in the negative PES group were alive at the end of the follow-up period with a median (range) follow-up time of 5 years (range, 4.5 to 6.3 years); none had symptomatic ventricular arrhythmia or required ICD at the conclusion of the study period. Event-free survival in the 2 groups is shown in Figure 2 . Kaplan-Meier survival estimation showed that survival was significantly higher in the PES negative group (PϽ0.0001).
Discussion
Sudden cardiac death or tachyarrhythmia may be the initial clinical presentation of CS. The true incidence of sudden death in CS is unknown, but may be up to 35%. 1 Autopsy studies in the United States suggest that up to 50% of patients with systemic sarcoidosis may have cardiac involvement, although the incidence of documented arrhythmia or conduction disturbance in this group is much lower. 1, 2 Because sudden cardiac death is a common cause of mortality in this population, it is likely that subclinical cardiac involvement and myocardial inflammation and scarring precedes the development of lethal arrhythmias. Although heart failure is a more common cause of death than arrhythmia in patients with advanced cardiac involvement, 12 patients with even small areas of myocardial scarring are at a heightened risk for reentrant ventricular arrhythmia.
Identification of patients with sarcoidosis who are at risk for sudden death has been difficult because of the low sensitivity of diagnostic testing. Endomyocardial biopsy often misses focal areas of myocardial involvement. Traditional noninvasive measures such as electrocardiography and echocardiography lack specificity and have not been validated in clinical studies. Advanced cardiac imaging has been used more recently to detect myocardial involvement in sarcoidosis. PET has good positive concordance in cases of established CS and better sensitivity than other scintigraphic techniques. 5, 13 More recently, Patel et al showed that CMR was more than twice as sensitive as the standard Japanese Ministry of Health and Welfare clinical criteria in diagnosing cardiac involvement in 81 patients with extracardiac sarcoidosis. 6 In their study, patients with evidence of myocardial damage on CMR had an 11.5-fold higher risk of cardiac death than patients with no evidence of damage.
Electrophysiological testing including programmed ventricular stimulation has been shown to be useful in risk stratification of patients with coronary artery disease and other forms of cardiomyopathy. 8,14 -16 PES has been reported to have some benefit in risk stratification of patients with CS. 10, 17 In a prospective study of 32 patients with sarcoidosis completed at this institution, 15 of whom received an ICD, Aizer et al demonstrated that induction of ventricular tachycardia during PES was associated with subsequent arrhythmic event, with a relative hazard of 4.5 in their cohort overall, and a higher hazard rate of 7.0 in patients without prior arrhythmia. 10 Nine of 12 patients with inducible sustained ventricular tachycardia received appropriate ICD therapy over an average follow-up of 84 months. Of note, the mean ejection fraction in their study was below 35%, indicating that many of the patients might have qualified for primary prevention ICDs under the present guidelines. 7 With advanced imaging techniques, patients with established systemic sarcoidosis will be increasingly screened for asymptomatic cardiac involvement. The greater sensitivity of PET and CMR will lead to the diagnosis of CS in an increasing number of patients. However, improved sensitivity is offset by a loss of specificity, as delayed hyperenhancement on CMR may be seen in a number of conditions, including ischemic heart disease, as noted by Patel et al. 6 Should all patients with systemic sarcoidosis and evidence of cardiac involvement on imaging studies receive an ICD? Patients with high-risk features including asymptomatic ventricular arrhythmia or significantly reduced left ventricular function otherwise qualifying for a primary prevention ICD are likely to benefit. However, the diagnosis of CS by imaging studies alone may overestimate the at-risk group, or be confounded by secondary cardiac diagnoses including coronary artery disease.
Based on present clinical indications, a significant proportion of patients with CS and LVEF of Ͻ35% would qualify for ICD implantation. There are no data to guide management of patients with minimal or mild left ventricular dysfunction who lack evidence of ventricular arrhythmia or conduction system disease. We demonstrate the additional benefit of electrophysiological testing in systemic sarcoidosis patients with evidence of CS by PET or CMR. Findings of the present study are applicable to a significant and largely undiagnosed proportion of patients with previously unrecognized CS. Absence of inducible ventricular arrhythmias in these patients was associated with good long-term prognosis. It may be that these patients have microgranulomas, but that fibrosis or scarring in the myocardium is insufficient to lead to reentrant ventricular arrhythmias. Although reduced LVEF was associated with a positive PES on our study, the degree of reduction at initial PES was mild to moderate in the positive group. Those patients with a reduced ejection fraction and a negative PES, who accounted for 37% of patients, were not at higher risk of events over the follow-up period.
The patients in our study appear to be representative of the population of sarcoidosis patients with preclinical cardiac involvement. Similar to the population in the study by Patel et al examining CMR for diagnosis of CS, mean ejection fraction was mildly diminished (mean EFϭ53.8%); in our study, it was lower in the group with positive PES (mean EFϭ36.4%). 6 Over their mean follow-up of 21 months, Patel et al reported that 19% of CMR positive patients had cardiac death. Six of the 76 patients (8%) in the present study with evidence of CS on imaging had events over a mean follow-up of 5 years, and all had a positive EP. The relatively smaller event rate in the present study compared with that reported by Patel et al (8% versus 19%) could be related to a larger number of patients with preserved left ventricular function. A larger prospective multicenter trial is needed to confirm the present study's findings.
The present study is limited by the relatively low event rate in this cohort, which is not unexpected given that the increased sensitivity of noninvasive imaging probably captures patients earlier in their disease course. In addition, it is difficult to predict asymptomatic ventricular arrhythmias in patients in the negative PES group because these patients did not undergo any monitoring. A necessary but limiting assumption of our analysis is that malignant ventricular arrhythmias in this group would lead to sudden death or, if survived, medical attention and implantation of a defibrillator. Furthermore, disease activity in sarcoidosis fluctuates, so that PES at a given point in time may not accurately predict long-term risk of ventricular arrhythmias and sudden cardiac death. Patients without events initially may later acquire an increased risk for arrhythmia over a longer follow-up period. Nonetheless, early recognition of inflammatory activity might prompt therapy with corticosteroids and could prevent longterm and potentially proarrhythmic scarring. Finally, although PES carries only minimal risk, a noninvasive means of predicting risk would be preferable.
Conclusions
In patients with biopsy-proven sarcoidosis and evidence of cardiac involvement on imaging studies who have no clinical manifestations of CS, a positive PES may help to identify those at risk for ventricular arrhythmia who thus would benefit from a primary prevention ICD. More importantly, patients in this cohort with a negative PES appear to have a benign course within the first several years after diagnosis. Larger prospective studies are needed to determine how ICD therapy could be optimally prescribed in this population.
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This article is dedicated to Dr Alvin S. Teirstein, who passed away on January 31, 2011. Dr Teirstein was Professor of Medicine at Mount Sinai Medical Center in New York. He was a pioneer and authority in sarcoid research, and we are grateful to him for his guidance to our work on cardiac sarcoidosis.
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